Inhibition of microRNA function by antimiR oligonucleotides

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Inhibition of microRNA function by antimiR oligonucleotides. / Stenvang, Jan; Petri, Andreas; Lindow, Morten; Obad, Susanna; Kauppinen, Sakari.

In: Silence, Vol. 3, No. 1, 2012.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Stenvang, J, Petri, A, Lindow, M, Obad, S & Kauppinen, S 2012, 'Inhibition of microRNA function by antimiR oligonucleotides', Silence, vol. 3, no. 1. https://doi.org/10.1186/1758-907X-3-1

APA

Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012). Inhibition of microRNA function by antimiR oligonucleotides. Silence, 3(1). https://doi.org/10.1186/1758-907X-3-1

Vancouver

Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence. 2012;3(1). https://doi.org/10.1186/1758-907X-3-1

Author

Stenvang, Jan ; Petri, Andreas ; Lindow, Morten ; Obad, Susanna ; Kauppinen, Sakari. / Inhibition of microRNA function by antimiR oligonucleotides. In: Silence. 2012 ; Vol. 3, No. 1.

Bibtex

@article{b37f8f5235624595a6b9e63e1d87ebf4,
title = "Inhibition of microRNA function by antimiR oligonucleotides",
abstract = "MicroRNAs (miRNAs) have emerged as important post-transcriptional regulators of gene expression in many developmental and cellular processes. Moreover, there is now ample evidence that perturbations in the levels of individual or entire families of miRNAs are strongly associated with the pathogenesis of a wide range of human diseases. Indeed, disease-associated miRNAs represent a new class of targets for the development of miRNA-based therapeutic modalities, which may yield patient benefits unobtainable by other therapeutic approaches. The recent explosion in miRNA research has accelerated the development of several computational and experimental approaches for probing miRNA functions in cell culture and in vivo. In this review, we focus on the use of antisense oligonucleotides (antimiRs) in miRNA inhibition for loss-of-function studies. We provide an overview of the currently employed antisense chemistries and their utility in designing antimiR oligonucleotides. Furthermore, we describe the most commonly used in vivo delivery strategies and discuss different approaches for assessment of miRNA inhibition and potential off-target effects. Finally, we summarize recent progress in antimiR mediated pharmacological inhibition of disease-associated miRNAs, which shows great promise in the development of novel miRNA-based therapeutics.",
author = "Jan Stenvang and Andreas Petri and Morten Lindow and Susanna Obad and Sakari Kauppinen",
year = "2012",
doi = "10.1186/1758-907X-3-1",
language = "English",
volume = "3",
journal = "Silence",
issn = "1758-907X",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Inhibition of microRNA function by antimiR oligonucleotides

AU - Stenvang, Jan

AU - Petri, Andreas

AU - Lindow, Morten

AU - Obad, Susanna

AU - Kauppinen, Sakari

PY - 2012

Y1 - 2012

N2 - MicroRNAs (miRNAs) have emerged as important post-transcriptional regulators of gene expression in many developmental and cellular processes. Moreover, there is now ample evidence that perturbations in the levels of individual or entire families of miRNAs are strongly associated with the pathogenesis of a wide range of human diseases. Indeed, disease-associated miRNAs represent a new class of targets for the development of miRNA-based therapeutic modalities, which may yield patient benefits unobtainable by other therapeutic approaches. The recent explosion in miRNA research has accelerated the development of several computational and experimental approaches for probing miRNA functions in cell culture and in vivo. In this review, we focus on the use of antisense oligonucleotides (antimiRs) in miRNA inhibition for loss-of-function studies. We provide an overview of the currently employed antisense chemistries and their utility in designing antimiR oligonucleotides. Furthermore, we describe the most commonly used in vivo delivery strategies and discuss different approaches for assessment of miRNA inhibition and potential off-target effects. Finally, we summarize recent progress in antimiR mediated pharmacological inhibition of disease-associated miRNAs, which shows great promise in the development of novel miRNA-based therapeutics.

AB - MicroRNAs (miRNAs) have emerged as important post-transcriptional regulators of gene expression in many developmental and cellular processes. Moreover, there is now ample evidence that perturbations in the levels of individual or entire families of miRNAs are strongly associated with the pathogenesis of a wide range of human diseases. Indeed, disease-associated miRNAs represent a new class of targets for the development of miRNA-based therapeutic modalities, which may yield patient benefits unobtainable by other therapeutic approaches. The recent explosion in miRNA research has accelerated the development of several computational and experimental approaches for probing miRNA functions in cell culture and in vivo. In this review, we focus on the use of antisense oligonucleotides (antimiRs) in miRNA inhibition for loss-of-function studies. We provide an overview of the currently employed antisense chemistries and their utility in designing antimiR oligonucleotides. Furthermore, we describe the most commonly used in vivo delivery strategies and discuss different approaches for assessment of miRNA inhibition and potential off-target effects. Finally, we summarize recent progress in antimiR mediated pharmacological inhibition of disease-associated miRNAs, which shows great promise in the development of novel miRNA-based therapeutics.

U2 - 10.1186/1758-907X-3-1

DO - 10.1186/1758-907X-3-1

M3 - Journal article

C2 - 22230293

VL - 3

JO - Silence

JF - Silence

SN - 1758-907X

IS - 1

ER -

ID: 44522424